Culay PA, Ferriol TR, Sarduy RCM, Cervantes NG

Language: Spanish
References: 16
Page: 408-418
PDF size: 225.34 Kb.

ABSTRACT

Background: ceftazidime is an antimicrobial belonging to the third generation cephalosporin’s family, it is indicated in the treatment of serious, simple or mixed bacterial infections, and its administration in continuous infusion allows optimizing the concentration of antibiotic to keep above their minimum inhibitory concentration.
Objective: to evaluate the use of ceftazidime in continuous infusion in nosocomial infections by Pseudomona aeruginosa.
Method: a case-control study was carried out on the use of ceftazidime in continuous infusion and intermittent doses, in patients admitted with a confirmed diagnostic of infection by Pseudomona aeruginosa in the Polyvalent Intermediate Care Unit and Trauma Unit rooms, at the University Hospital Manuel Ascunce, from March 2009 to March 2010. Nonrandom sample consisted of 84 patients with infection by Pseudomona aeruginosa and received treatment with ceftazidime 42 cases and an equal number of controls.
Results: the 49 % of the total sample had 60 years and older, diabetes mellitus as associated comorbidity presented in 52 patients, favorable evolution corresponded to 34 patients which ceftazidime in continuous infusion was administered.
Conclusions: the infectionby Pseudomona aeruginosa was more frequent in patients older than 60 years and associated comorbidity was diabetes mellitus. Ceftazidime administration in continuous infusion showed better results than intermittent dose administration.

REFERENCES

1. Hoffman F. Microbiología y farmacocinética de las cefalosporinas parenterales. Basilea: La Roche; 1984.

2. Goodman L, Gilman A. Las bases farmacológicas de la terapéutica. T 2. La Habana: Editorial Ciencias Médicas; 1981.

3. Birnbaum J, Stapley E, Miller A. Cefoxitin, semisynthetic cephamicin: a microbiologic overview. J Antimicrob Chemother. 1978; 4:15-32.

4. Norrby S. Role of the cephalosporin in the treatment of bacterial meningitis in adults. Am J Med. 1985; 79(Suppl 20):556-71.

5. Lacy M, Tessier PR, Nicolau D, Nightingale C, Quintiliani R. Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci. Int J Antimicrob Agents. 2000 Jun; 15(1):25-30.

6. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2010; 45(9):2460-7.

7. McKinnon P, Paladino J, Schentag J. Evaluation of area under the inhibitory curve (AUIC) and time above the mínimum inhibitory concentration (T> MIC) as predictors outcome for Cefepime and Ceftazidime in serious bacterial infections. INT J Antimicrob Agents. 2008;31:345-51.

8. Rhomberg P, Fritsche T, Sader H. Antimicrobial susceptibility pattern comparisons among intensive care unit and general Ward Gram-negative isolates from the Meropenem Yearly susceptibility test Information Collection Program. Diagn Microbiol Inject Dis. 2006;56:57-62.

9. Neuhauser M, Weinstein R, Rydman R. Antibiotic resistance among Gram-negative bacilli in us intensive care unit: Implications for fluoroquinolone use. JAMA. 2003; 289:285-8.

10. Roberts J, Paratz E. Continouos infusión of beta-lactam antibiotic in severa infections, A review of its role. Int J Antimicrob Agents. 2007;38:11-8.

11. Sakka S, Glauner A, Bulitta J. Populations pharmacokinetics and pharmacodynamics of continouos versus short-term infusión of Imipenem-cilastatin in critically ill patients in a randomized controlled trial. Antimicrob Agents Chemother. 2007;51:3304-10.

12. Ross J, Bulitta J, lipman J. Pharmacokinetic /pharmacodynamic propertiers of Cefpirome in critically ill patients. Intensive Care Med. 2007;33:781-8.

13. McNabb J, Nightingale H, Quintiliani R. Cost-effectiveness of Ceftazidime by continouos infusión versus intermittent infusión for nosocomial pneumonia. Pharmacotherapy. 2010; 21:549-55.

14. Roberts J, Webb S, Paterson D, Kwok M, Lipman J. A Systematic review on clinical benefits of continouos administration of B-lactam antibiotics. Crit Care Med. 2009; 7:2071-8.

15. Lodise T, Lomaestro B, Drusand G. Piperacillin _tazobactam for Pseudomona aeruginosa infection:clinical implications of extended -;infusion dosind strategy. Clin Infect Dis. 2008; 44:357-63.

16. Lorente L, Huidobro S, Martin M. Meropenem administration by intermittent infusión versus continouos infusión for the treatment of nosocomial pneumonia. Crit Care. 2005; 9(1):38-43.